B
Basetti Madhu
Researcher at University of Cambridge
Publications - 37
Citations - 4909
Basetti Madhu is an academic researcher from University of Cambridge. The author has contributed to research in topics: Prostate cancer & Cancer. The author has an hindex of 20, co-authored 37 publications receiving 4404 citations. Previous affiliations of Basetti Madhu include Sahlgrenska University Hospital & Cancer Research UK.
Papers
More filters
Journal ArticleDOI
Inhibition of Hedgehog Signaling Enhances Delivery of Chemotherapy in a Mouse Model of Pancreatic Cancer
Kenneth P. Olive,Michael A. Jacobetz,Christian Davidson,Aarthi Gopinathan,Aarthi Gopinathan,Dominick J.O. McIntyre,Davina J. Honess,Basetti Madhu,Mae A. Goldgraben,Meredith E. Caldwell,David Allard,Kristopher K. Frese,Gina M. DeNicola,Gina M. DeNicola,Christine Feig,Chelsea Combs,Stephen P. Winter,Heather Ireland-Zecchini,Stefanie Reichelt,William J. Howat,Alex R. Chang,Mousumi Dhara,Lifu Wang,Lifu Wang,Felix Rückert,Robert Grützmann,Christian Pilarsky,Kamel Izeradjene,Sunil R. Hingorani,Pearl S. Huang,Susan E. Davies,William Plunkett,Merrill J. Egorin,Ralph H. Hruban,Nigel Whitebread,Karen McGovern,Julian Adams,Christine A. Iacobuzio-Donahue,John R. Griffiths,David A. Tuveson +39 more
TL;DR: Studying a mouse model of PDA that is refractory to the clinically used drug gemcitabine, it is found that the tumors in this model were poorly perfused and poorly vascularized, properties that are shared with human PDA.
Journal ArticleDOI
The androgen receptor fuels prostate cancer by regulating central metabolism and biosynthesis
Charles E. Massie,Andy G. Lynch,Antonio Ramos-Montoya,Joan Boren,Rory Stark,Ladan Fazli,Anne Y. Warren,H Scott,Basetti Madhu,N L Sharma,Helene Bon,Vinny Zecchini,D. Smith,Gina M. DeNicola,Nik Mathews,Michelle Osborne,James Hadfield,Stewart MacArthur,Boris Adryan,Scott K. Lyons,Kevin M. Brindle,John R. Griffiths,Martin E. Gleave,Paul S. Rennie,David E. Neal,Ian G. Mills +25 more
TL;DR: Cal calcium/calmodulin‐dependent protein kinase kinase 2 is highlighted, which it is shown is overexpressed in prostate cancer and regulates cancer cell growth via its unexpected role as a hormone‐dependent modulator of anabolic metabolism.
Journal ArticleDOI
Combined metabolomic and proteomic analysis of human atrial fibrillation.
Manuel Mayr,Shamil Yusuf,Graeme Weir,Yuen-Li Chung,Ursula Mayr,Xiaoke Yin,Christophe Ladroue,Basetti Madhu,Neil Roberts,Ayesha I. De Souza,Salim Fredericks,Marion Stubbs,John R. Griffiths,Marjan Jahangiri,Qingbo Xu,A. John Camm +15 more
TL;DR: The present study characterized the metabolic adaptation to persistent AF, unraveling a potential role for ketone bodies, and demonstrated that discordant metabolic alterations are evident in individuals susceptible to post-operative AF.
Journal ArticleDOI
Choline Kinase Alpha as an Androgen Receptor Chaperone and Prostate Cancer Therapeutic Target.
Mohammad Asim,Charles E. Massie,Folake A Orafidiya,Nelma Pértega-Gomes,Anne Y. Warren,Mohsen Esmaeili,Luke A. Selth,Heather I. Zecchini,Katarina Luko,Arham Qureshi,Ajoeb Baridi,Suraj Menon,Basetti Madhu,Carlos Escriu,Scott K. Lyons,Sarah L. Vowler,Vincent Zecchini,Greg Shaw,Wiebke Hessenkemper,Roslin Russell,Hisham Mohammed,Niki Stefanos,Andy G. Lynch,Elena Grigorenko,Clive D'Santos,Chris Taylor,Alastair D. Lamb,Rouchelle Sriranjan,Jiali Yang,Rory Stark,Scott M. Dehm,Paul S. Rennie,Jason S. Carroll,John R. Griffiths,Simon Tavaré,Ian G. Mills,Ian G. Mills,Iain J. McEwan,Aria Baniahmad,Wayne D. Tilley,David E. Neal +40 more
TL;DR: CHKA is the first kinase identified as an AR chaperone, providing, to the authors' knowledge, the first evidence for kinases as molecular chaperones, making CHKA both a marker of tumor progression and a potential therapeutic target for PCa.
Journal ArticleDOI
Noninvasive magnetic resonance spectroscopic pharmacodynamic markers of the choline kinase inhibitor MN58b in human carcinoma models.
Nada M.S. Al-Saffar,Helen Troy,Ana Ramírez de Molina,Laura E. Jackson,Basetti Madhu,John R. Griffiths,Martin O. Leach,Paul Workman,Juan Carlos Lacal,Ian Judson,Yuen-Li Chung +10 more
TL;DR: The decrease in phosphocholine, total choline, and phosphomonoesters may have potential as noninvasive pharmacodynamic biomarkers for determining tumor response following treatment with choline kinase inhibitors.